ArticleThe oncologist2026
Use and overuse of positron emission tomography for patients with metastatic colorectal cancer.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In all healthcare systems, and particularly those that are resource limited, using diagnostic techniques efficiently is essential. According to consensus guidelines, standard computed tomography (CT) imaging without positron emission tomography (PET) is usually sufficient for the management of metastatic colorectal cancer (mCRC). This retrospective national cohort study evaluated the use of PET in mCRC management among members of Clalit Health Services (CHS, the largest Israeli health maintenance organization covering >50% of the Israeli population), utilizing the CHS central database. The cohort included CHS members diagnosed with mCRC between 2017 and 2022 (N = 998). The median number of PETs performed per patient was 5. Overall, during the follow-up period (up to 10/2024), 44% of patients underwent >5PETs, and the median number of PETs performed per patient per year was 2.2. In conclusion, our study identified a substantial overuse of PET in the management of mCRC in Israel, marking a divergence from clinical guidelines. More research is needed to assess this in other diseases and in other countries/regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.